| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination |
|
言語 |
en |
| 作成者 |
Sakamoto, Shinjiro
Yoshitomi, Munehiro
Yutani, Shigeru
Terazaki, Yasuhiro
Yoshiyama, Koichi
Ioji, Tetsuya
Matsueda, Satoko
Yamada, Akira
Takamori, Shinzo
Itoh, Kyogo
Hattori, Noboru
Kohno, Nobuoki
Sasada, Tetsuro
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
© Cancer Vaccine Center, Kurume University. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properlycited. Themoral rights of the named author(s) have been assertted. |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
ARG1 |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
biomarker |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
MMP-9 |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
MPO |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
multivariate Cox regression analysis |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
personalized peptide vaccine |
| 内容記述 |
|
|
内容記述 |
Since cancer vaccines do not always elicit beneficial effects in treated patients, identification of biomarkers for predicting clinical outcomes would be highly desirable. We previously reported that abnormal granulocytes present in peripheral blood mononuclear cells (PBMC) may contribute to poor prognosis in advanced prostate cancer patients receiving personalized peptide vaccination (PPV). In the current study, we examined whether soluble factors derived from granulocytes, such as matrix metalloproteinase 9 (MMP-9), myeloperoxidase (MPO), and arginase 1 (ARG1), and inhibitory cytokine TGFβ in pre-vaccination plasma were useful for predicting prognosis after PPV in advanced cancer patients. In biliary tract cancer (n=25), multivariate Cox regression analysis demonstrated that patients with higher plasma MMP-9 levels had a significantly worse overall survival (OS) [hazard ratio (HR) = 4.637, 95% confidence interval (CI) = 1.670 - 12.877, P = 0.003], whereas MPO, ARG1, or TGFβ levels were not correlated with OS. Similarly, patients with higher MMP-9 levels showed worse prognosis than those with lower MMP-9 levels in other types of advanced cancers, including non-small cell lung cancer (n=32, P = 0.037 by log-rank test), and pancreatic cancer (n=41, P = 0.042 by log-rank test). Taken together, plasma MMP-9 levels before vaccination might be potentially useful as a biomarker for selecting advanced cancer patients who would benefit from PPV. |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
This study was supported by a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan; a research program of the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan; and Kurozumi Medical Foundation. |
| 出版者 |
|
|
出版者 |
Taylor & Francis Group, LLC |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1080/21645515.2015.1075107 |
| 関連情報 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
26325075 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1080/21645515.2015.1075107 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2164-5515 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2164-554X |
| 開始ページ |
|
|
開始ページ |
2784 |
| 書誌情報 |
Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics
巻 11,
号 12,
p. 2784-2789,
発行日 2015-12-23
|
| 旧ID |
48659 |
HumVaccinImmunother_11_2784.pdf (280.2 KB)
